SCHEMBL8317341

SCHEMBL8317341

CNC(=O)c1ccccc1OC(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 4/20 0.59
KCNK9 Q9NPC2 4/20 0.59
F2R P25116 1/20 0.53
GAA P10253 1/20 0.53
KAT2B Q92831 1/20 0.50
BAZ2B Q9UIF8 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
HCN1 O60741 1/20 0.48
CLK1 P49759 1/20 0.48
PNLIP P16233 1/20 0.47
OPRM1 P35372 1/20 0.46
PLK1 P53350 2/20 0.46
CTSD P07339 1/20 0.45
ANO1 Q5XXA6 1/20 0.44
PDK2 Q15119 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201210 0.84 KCNK3 (0.57) KCNK3KCNK9F2RGAARXFP1
SCHEMBL19654139 0.84 KAT2B (0.51) KCNK3KCNK9GAAKAT2BBAZ2B
SCHEMBL2061615 0.84 KCNK3 (0.48) KCNK3KCNK9F2RGAAKAT2B
SCHEMBL13761351 0.83 KCNK3 (0.61) KCNK3KCNK9F2RRXFP1HCN1
SCHEMBL16797882 0.83 KCNK3 (0.60) KCNK3KCNK9F2RGAARXFP1
SCHEMBL22023934 0.83 KCNK3 (0.47) KCNK3KCNK9F2RGAAKAT2B
SCHEMBL376957 0.83 CTSD (0.62) KCNK3KCNK9F2RGAARXFP1
SCHEMBL29646406 0.83 CTSD (0.62) KCNK3KCNK9F2RGAARXFP1
SCHEMBL13753068 0.82 F2R (0.56) KCNK3KCNK9F2RRXFP1HCN1
Hydrochloric Acid SCHEMBL5800475 0.81 CTSD (0.60) KCNK3KCNK9F2RGAARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12496297-B1 Compositions of autophagy modulating agents and uses thereof WASHINGTON UNIVERSITY (US) 2025-12-16 US disclosed
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-30 US disclosed
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
US-9901572-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 US disclosed
US-20170216263-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-03 US disclosed
US-9663466-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-30 US disclosed
CN-104245698-B Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL CO.,LTD. (JP) 2016-11-30 CN disclosed
EP-2785693-B1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONES AS MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-18 EP disclosed
US-20150315144-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-11-05 US disclosed
CN-104245698-A Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL 2014-12-24 CN disclosed
US-7179802-B2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2007-02-20 US disclosed
US-7179802-B2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2007-02-20 US disclosed
EP-0636625-B1 Tricyclic diazepines vasopressin and oxytocin antagonists AMERICAN CYANAMID CO (US) 1999-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 KCNK3 2230/4885KCNK9 1293/4885F2R 2745/4885
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS KDM5A, KDM5C, KDM5B KCNK3 2606/4885KCNK9 3018/4885F2R 4470/4885
US-20170216263-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 KCNK3 2230/4885KCNK9 1293/4885F2R 2745/4885
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 KCNK3 2230/4885KCNK9 1293/4885F2R 2745/4885
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 KCNK3 2230/4885KCNK9 1293/4885F2R 2745/4885
US-20150315144-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 KCNK3 2230/4885KCNK9 1293/4885F2R 2745/4885
US-12496297-B1 Compositions of autophagy modulating agents and uses thereof BECN1, TFEB, ATG7 KCNK3 4707/4885KCNK9 4803/4885F2R 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.